col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world


65 Results       Page 1

 [1] 
Elsevier: Therapies
  original article Date Title Authors   All Authors
1 [GO] 2023―Aug―30 Autoimmune hepatitis following mRNA COVID-19 vaccine* Ahmed Zaiem, Khouloud Ferchichi, Ghozlane Lakhoua, Widd Kaabi, Imen Aouinti, Sana Rebii Debbiche, et al. (+4)
2 [GO] 2023―Jun―15 Augmentation des surdoses et décès en lien avec la consommation de méthadone durant la crise sanitaire liée au COVID-19 en 2020 Elisabeth Frauger, Nathalie Fouilhé, Clémence Lacroix, Amélie Daveluy, Reynald Le Boisselier, Célian Bertin, et al. (+11)
3 [GO] 2023―Jun―07 Acute angle closure glaucoma following COVID-19 vaccination* Yasmine Salem Mahjoubi, Israa Dahmani, Ines Souilem, Imen Aouinti, Sarrah Kastalli, Riadh daghfous, Sihem El Aidli
4 [GO] 2023―Jun―07 Hydroxychloroquine and COVID-19: the endgame! Dominique Deplanque
5 [GO] 2023―Jun―02 Why the article that led to the widespread use of hydroxychloroquine in COVID-19 should be retracted? Damien Barraud, Lonni Besancon, Elisabeth M Bik, Eric Billy, Franck Clarot, Fabrice Frank, et al. (+7)
6 [GO] 2023―May―25 Response to Letter “Only blames SARS-CoV-2 vaccination for facial palsy after alternative etiologies have been ruled out” Morgane Chamboux, Corinne Simon, Frédérique Beau-Salinas, Anaïs Maurier, Marie Sara Agier, Eve Marie Thillard, et al. (+2)
7 [GO] 2023―May―17 Only blame SARS-CoV-2 vaccination for facial palsy after alternative etiologies have been ruled out Josef Finsterer, Fulvio A Scorza
8 [GO] 2023―Mar―07 Role of spontaneous reporting in investigating the relationship between mRNA COVID-19 vaccines and myocarditis: the French perspective Francesco Salvo, Antoine Pariente, Marie Blanche Valnet-Rabier, Milou-Daniel Drici, Clement Cholle, Clement Mathieu, et al. (+5)
9 [GO] 2023―Mar―07 Monitoring the safety of drugs and COVID-19 vaccines by the French Pharmacovigilance Centers during the pandemic: a win-win bet with Health Authorities! Annie Pierre Jonville-Bera, Sophie Gautier, Joëlle Micallef, Nathalie Massy, Marina Atzenhoffer, Aurélie Grandvuillemin, Milou-Daniel Drici
10 [GO] 2023―Feb―22 French pharmacovigilance survey of casirivimab - imdevimab monoclonal antibodies in coronavirus disease (COVID-19) Claire de Canecaude, François Montastruc, Sandrine Bergeron, Paola Sanchez Pena, Aurélie Grandvuillemin
11 [GO] 2023―Feb―22 Pharmacovigilance des médicaments et des vaccins contre la COVID-19 durant la pandémie: comment le Réseau français des centres régionaux de pharmacovigilance a relevé le défi? Annie Pierre Jonville-Bera, Sophie Gautier, Joëlle Micallef, Nathalie Massy, Marina Atzenhoffer, Milou-Daniel Drici, Aurélie Grandvuillemin
12 [GO] 2023―Feb―16 Peripheral facial palsy post SARS-CoV-2 vaccine: a regional pharmacovigilance cases series Morgane Chamboux, Corinne Simon, Frédérique Beau-Salinas, Anaïs Maurier, Marie Sara Agier, Eve Marie Thillard, et al. (+2)
13 [GO] 2023―Jan―21 Covid-19 Et Vaccins À Adénovirus: Expérience Française De Suivi Renforcé De Pharmacovigilance Nathalie Massy, Marina Atzenhoffer, Charlène Boulay, Pauline Pecquet, Fanny Ledys, Jean-Luc Cracowski, et al. (+3)
14 [GO] 2023―Jan―20 Contribution of real-life studies in France during the COVID-19 pandemic and for the national pharmaco-epidemiological surveillance of COVID-19 vaccines Mahmoud Zureik, François Cuenot, Alain Weill, Rosemary Dray-Spira
15 [GO] 2023―Jan―20 Impact of coronavirus disease 2019 on contraception use in France Noemie Roland, Jerome Drouin, David Desplas, Lise Duranteau, Francois Cuenot, Rosemary Dray-Spira, et al. (+2)
16 [GO] 2023―Jan―20 Pharmacovigilance follow-up of patients in the context of the COVID 19 pandemic Aurélie Grandvuillemin, Fanny Rocher, Marie Blanche Valnet-Rabier, Milou-Daniel Drici, Anne Dautriche
17 [GO] 2022―Dec―10 Impact des confinements sur les hospitalisations survenues dans un contexte d’usage de substances psycho-actives en France selon l’âge pendant la pandémie de COVID-19 Justine Perino, Hanta Ramaroson, Nathalie Ong, Julien Bezin, Véronique Gilleron, Amélie Daveluy, Marie Tournier
18 [GO] 2022―Dec―10 Chronic spontaneous urticaria following vaccination against SARS-CoV-2 Ahmed Zaiem, Yasmine Salem Mahjoubi, Imen Aouinti, Ghozlane Lakhoua, Widd Kaabi, Sarrah Kastalli, et al. (+3)
19 [GO] 2022―Dec―10 The need to shed light on potential insidious SARS-CoV-2 post-vaccination pituitary lesions Ach Taieb, Euch Mounira El
20 [GO] 2022―Dec―10 Central diabetes insipidus, hypophysitis and SARS-CoV-2 vaccine: correspondence Rujittika Mungmunpuntipantip, Viroj Wiwanitkit
21 [GO] 2022―Oct―31 Safety profile of the lopinavir/ritonavir combination before and during the SARS-CoV2 pandemic Pauline Lory, Sandrine Combret, Joelle Michot, Gwenaelle Veyrac, Laurent Chouchana, Aurélie Grandvuillemin
22 [GO] 2022―Oct―06 Central diabetes insipidus revealing a hypophysitis induced by SARS-CoV-2 vaccine Taieb Ach, Fatma Kammoun, Hamza El Fekih, Nassim Ben Haj Slama, Siwar Kahloun, Fatma Ben Fredj, et al. (+2)
23 [GO] 2022―Aug―01 Impact of the COVID-19 pandemic on antiviral drug development for other community-acquired respiratory viruses’ infections Zineb Ghrieb, Maud Salmona, David Michonneau, Charles De Saisset, Souhil Allaoua, Jean-Jacques Kiladjian, et al. (+3)
24 [GO] 2022―Jul―13 The winding 12-month journey of the AstraZeneca COVID-19 vaccine since its first administration to humans. Effects of the AstraZeneca COVID-19 vaccination Rafael Dal-Ré
25 [GO] 2022―Jun―30 Hospitalisations après consommation de substances psychoactives pendant la pandémie de Covid-19 Claire Dumoulin, Nathalie Ong, Hanta Ramaroson, Louis Létinier, Ghada Miremont-Salamé, Véronique Gilleron, et al. (+2)
26 [GO] 2022―May―19 COVID-19: GLOBAL INEQUALITY IN SCIENCE Bakthavachalam Elango
27 [GO] 2022―May―07 Public perceptions of the association between drug effectiveness and drug novelty in France during the COVID-19 pandemic Émilien Schultz, Léo Mignot, Jeremy Ward, Daniela Boaventura, Christian Chabannon, Julien Mancini
28 [GO] 2022―Apr―27 Adverse drug reactions and ivermectin in COVID-19 Jean-Louis Montastruc
29 [GO] 2022―Apr―26 Cluster headache after COVID-19 vaccination with Comirnaty: a signal in pharmacovigilance database* Michaël Rochoy, Eric Billy, Franck Clarot, Victor Dumortier, Sophie Gautier, Romain Barus
30 [GO] 2022―Apr―20 Adverse drug reactions associated with ivermectin use for COVID-19 reported in the WHO’s pharmacovigilance database Jeremy T. Campillo, Jean-Luc Faillie
31 [GO] 2022―Apr―20 Management of drug-drug interactions with nirmatrelvir/ritonavir in patients treated for Covid-19: Guidelines from the French Society of Pharmacology and Therapeutics (SFPT) Florian Lemaitre, Matthieu Grégoire, Caroline Monchaud, Stéphane Bouchet, Béatrice Saint-Salvi, Elisabeth Polard, et al. (+12)
32 [GO] 2021―Dec―28 Comparative study of the adverse event profile of hydroxychloroquine before and during the Sars-CoV2 pandemic Pauline Lory, Jeffrey Lombardi, Clémence Lacroix, Paola Sanchez-Pena, Serena Romani, Aurélie Grandvuillemin
33 [GO] 2021―Dec―04 Lessons from the COVID-19 pandemic Philippe Lechat
34 [GO] 2021―Oct―25 A historical cohort stuy to investigation of statins safety in COVID-19 hospitalized patients Saeed Nateghi, Mohammad Mahmoudi Gomari, Hadiseh Hosamirudsari, Behnam Behnoush, Asma Razmjoofard, Goli Azimi, et al. (+3)
35 [GO] 2021―Oct―08 Peptides-based therapeutics: emerging potential therapeutic agents for COVID-19 Jagat Narayan Shah, Guang-Qin Guo, Anand Krishnan, Muthusamy Ramesh, Naresh Kumar Katari, Mohd Shahbaaz, et al. (+3)
36 [GO] 2021―Jul―27 Balancing the reactogenicity of the ChAdOx1 nCov-19 vaccine against SARS-CoV-2 and the urgent need of a large immunization in healthcare workers Laurent Chouchana, Etienne Canouï, Rui Batista, Adrien Contejean, Alain Cariou, Jean Marc Treluyer, Caroline Charlier
37 [GO] 2021―Jun―01 COVID-19 vaccines and pregnancy: what do we know? Judith Cottin, Justine Benevent, Sophie Khettar, Isabelle Lacroix
38 [GO] 2021―May―28 COVID-19 vaccines: a perspective from social pharmacology Jean-Louis Montastruc, Margaux Lafaurie, Claire de Canecaude, François Montastruc, Haleh Bagheri, Geneviève Durrieu, Agnès Sommet
39 [GO] 2021―May―28 COVID-19: Pharmacology has kept the science ship running during the storm Mathieu Molimard, Vincent Richard, Jean-Luc Cracowski
40 [GO] 2021―May―12 Efficacy of Covid-19 vaccines: from clinical trials to real life Dominique Deplanque, Odile Launay
41 [GO] 2021―May―07 French organization for the Pharmacovigilance of COVID-19 vaccines: a major challenge Clémence Lacroix, Francesco Salvo, Valérie Gras-Champel, Sophie Gautier, Nathalie Massy, Marie-Blanche Valnet-Rabier, et al. (+6)
42 [GO] 2021―May―07 Evaluation of Covid-19 vaccines: pharmacoepidemiological aspects Antoine Pariente, Julien Bezin
43 [GO] 2021―Apr―29 Eruption eczématiforme après le vaccin par Pfizer-BioNTech COVID-19* Nihal Bekkali, Tanguy Allard, Eric Estève, Céline Lengellé
44 [GO] 2021―Apr―02 Type I interferons as the potential mechanism linking mRNA COVID-19 vaccines to Bell’s palsy Thomas Soeiro, Francesco Salvo, Antoine Pariente, Aurélie Grandvuillemin, Annie-Pierre Jonville-Béra, Joëlle Micallef
45 [GO] 2021―Mar―06 Pneumopathie médicamenteuse ou liée à la COVID-19: un train peut en cacher un autre! Mélanie Vasseur, Marine Tambon, Mireille Gony, Nicolas Lebrun, Haleh Bagheri
46 [GO] 2021―Feb―16 Un exemple de réorganisation dans le fonctionnement d’un Centre d’investigations cliniques en période de confinement national suite à la pandémie COVID-19 Zineb Ghrieb, Souhil Allaoua, Jin Huang, Nathalie Langner, Florène François, Corinne Maréchal, et al. (+8)
47 [GO] 2021―Jan―28 Pharmacokinetics and pharmacodynamics of hydroxychloroquine in hospitalized patients with COVID-19 Noël Zahr, Saik Urien, Benoit Llopis, Valérie Pourcher, Olivier Paccoud, Alexandre Bleibtreu, et al. (+11)
48 [GO] 2021―Jan―20 Drug consumption during prolonged lockdown due to Covid-19 as observed in French addiction center Mathieu Chappuy, Marie Peyrat, Olivier Lejeune, Nathalie Duvernay, Brigitte David, Philippe Joubert, Philippe Lack
49 [GO] 2021―Jan―19 DPP-4 inhibitors and severe course of illness in patients with COVID-19 Béatrice Bouhanick, Jean-Luc Cracowski, Jean-Luc Faillie
50 [GO] 2020―Dec―26 A meta-analysis on the preadmission use of DPP-4 inhibitors and risk of a fatal or severe course of illness in patients with COVID-19 Chia Siang Kow, Syed Shahzad Hasan
51 [GO] 2020―Nov―01 Harnessing immunotherapy to combat COVID-19: A modern snake oil or silver bullet? Shivshankar Malkarjun Gunjegaonkar, Thukani Sathanantham Shanmugarajan, Mohanasundaram Arunsundar, Uppuluri Varuna Naga Venkata Arjun, Kadirrel Devi, Sagar Baliram Wankhede, Velayutham Ravichandiran
52 [GO] 2020―Oct―17 Modifications pharmacocinétiques liées à une infection aigue. Exemples issus de la pandémie de SARS-Cov2 Anaëlle Chavant, Elodie Gautier-Veyret, Stéphanie Chhun, Romain Guilhaumou, Françoise Stanke-Labesque
53 [GO] 2020―Jul―22 COVID-19 and NSAIDs: Primum non nocere Joëlle Micallef, Thomas Soeiro, Annie-Pierre Jonville Béra
54 [GO] 2020―Jul―12 No arguments for extra risk from ibuprofen in SARS-COV2 infection Nicholas Moore
55 [GO] 2020―Jun―27 NSAIDs may increase the risk of thrombosis and acute renal failure in patients with COVID-19 infection Medine Cumhur Cure, Adem Kucuk, Erkan Cure
56 [GO] 2020―Jun―27 Challenges of autoimmune rheumatic disease treatment during the COVID-19 pandemic: a review Lucile Grange, Philippe Guilpain, Marie-Elise Truchetet, Jean-Luc Cracowski
57 [GO] 2020―Jun―23 Addictovigilance contribution during COVID-19 epidemic and lockdown in France Maryse Lapeyre-Mestre, Alexandra Boucher, Amelie Daveluy, Valerie Gibaja, Emilie Jouanjus, Michel Mallaret, et al. (+2)
58 [GO] 2020―Jun―06 Ultrafast response of the French Society of Pharmacology and Therapeutics to the COVID-19 pandemic Jean-Luc Cracowski, Mathieu Molimard, Vincent Richard
59 [GO] 2020―May―23 Chloroquine and hydroxychloroquine in the management of COVID-19: much kerfuffle but little evidence Matthieu Roustit, Romain Guilhaumou, Mathieu Molimard, Milou Drici, Silvy Laporte, Jean-Louis Montastruc
60 [GO] 2020―May―20 Renin-angiotensin-aldosterone system and COVID-19 infection Joachim Alexandre, Jean-Luc Cracowski, Vincent Richard, Béatrice Bouhanick
61 [GO] 2020―May―15 Diabetes and COVID-19 Béatrice Bouhanick, Jean Luc Cracowski, Jean Luc Faillie
62 [GO] 2020―May―15 Pharmacological characteristics of patients infected with SARS-Cov-2 admitted to Intensive Care Unit in South of France François Montastruc, Charles Romano, Jean-Louis Montastruc, Stein Silva, Thierry Seguin, Vincent Minville, et al. (+3)
63 [GO] 2020―May―07 Non-steroidal anti-inflammatory drugs, pharmacology, and COVID-19 infection Joëlle Micallef, Thomas Soeiro, Jonville-Béra Annie-Pierre
64 [GO] 2020―May―07 “Off-label” use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: a survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers Alexandre Gérard, Serena Romani, Audrey Fresse, Delphine Viard, Nadège Parassol, Aurélie Granvuillemin, et al. (+3)
65 [GO] 2020―May―05 Adverse drug reactions of hydroxychloroquine: Analysis of French pre-pandemic SARS-CoV2 pharmacovigilance data Aurélie Grandvuillemin, Audrey Fresse, Clément Cholle, Samir Yamani, Anne Dautriche
 [1] 

65 Results       Page 1


[de][en]

Last change 2023―Oct―27 12:08:13 UTC

© Daten-Quadrat 2022       Done in 0.014 sec